{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:08:11Z","timestamp":1789603691070,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1053\/j.seminhematol.2010.06.001","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T05:04:19Z","timestamp":1285736659000},"page":"319-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Can We and Should We Improve on Frontline Imatinib Therapy for Chronic Myeloid Leukemia?"],"prefix":"10.1053","volume":"47","author":[{"given":"Carmen","family":"Fava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.06.001_bib1","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib2","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib3","first-page":"1126","article-title":"International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib6","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib7","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib9","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib10","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin Cancer Res."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib11","first-page":"27","article-title":"Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy","volume":"110","author":"Guilhot","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib12","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib15","unstructured":"2009. NccnNCpgioCMLV."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib16","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","article-title":"A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors","volume":"19","author":"Robin","year":"2005","journal-title":"Leukemia"},{"issue":"Suppl 15","key":"10.1053\/j.seminhematol.2010.06.001_bib17","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.2146\/ajhp070482","article-title":"Targeted chronic myeloid leukemia therapy: seeking a cure","volume":"64","author":"Fausel","year":"2007","journal-title":"Am J Health Syst Pharm."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00001622-200403000-00002","article-title":"Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant","volume":"16","author":"Angstreich","year":"2004","journal-title":"Curr Opin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib19","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib21","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib22","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2007-08-103499","article-title":"Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party","volume":"113","author":"Castagnetti","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib23","first-page":"2149","article-title":"Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT Trial Study Group","volume":"108","author":"Cortes","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2010.06.001_bib24","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1200\/jco.2006.24.18_suppl.6535","article-title":"High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up","volume":"24","author":"Aoki","year":"2006","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib26","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib27","first-page":"1125","article-title":"Maintaining imatinib >=600 mg daily in the first 12 months of chronic phase CML treatment is associated with superior event-free survival at 5 years","volume":"114","author":"Osborn","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib28","first-page":"337","volume":"114","author":"Baccarani","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib30","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib31","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2003-04-1010","article-title":"Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase","volume":"102","author":"Gardembas","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib32","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib33","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.12265","article-title":"Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib34","first-page":"340","volume":"114","author":"Guilhot","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"suppl 2","key":"10.1053\/j.seminhematol.2010.06.001_bib35","first-page":"1093","volume":"94","author":"Rousselot","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib36","first-page":"339","article-title":"Randomized comparison of imatinib 800 mg vs. imatinib 400 mg +\/\u2212 IFN in newly diagnosed BCR\/ABL positive chronic phase CML: analysis of molecular remission at 12 months; the German CML-Study IV","volume":"114","author":"Hehlmann","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib37","first-page":"862","article-title":"Optimaization of imatinib therapy by combination. 5 year survival and response results of the pilot phase of the randomized German CML Study IV","volume":"114","author":"Pletsch","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib38","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2007-08-107482","article-title":"Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia","volume":"111","author":"Deenik","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib40","first-page":"1129","article-title":"Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes","volume":"114","author":"Kantarjian","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib41","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib44","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib45","first-page":"2205","article-title":"Nilotinib 800 mg daily as frontline therapy of Ph + chronic myeloid leukemia: dose delivered and safety profile for the GIMEMA CML Working Party","volume":"114","author":"Rosti","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib46","first-page":"3294","article-title":"Nilotinib 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: preliminary results of the ICORG 0802 phase 2 study","volume":"114","author":"O'Dwyer","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib47","first-page":"LBA-1","article-title":"Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial","volume":"114","author":"Saglio","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.001_bib48","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"key":"10.1053\/j.seminhematol.2010.06.001_bib49","first-page":"1098","article-title":"Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib","volume":"112","author":"Cortes","year":"2008","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:36Z","timestamp":1758522036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0037196310000752"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can We and Should We Improve on Frontline Imatinib Therapy for Chronic Myeloid Leukemia?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}